Isavuconazole (Cresemba)

Indications

  • Invasive Aspergillosis (see Aspergillus, [[Aspergillus]]): FDA-approved in 3/15
    • May be used as an alternative to voriconazole (see Voriconazole, [[Voriconazole]])
  • Mucormycosis (see Mucormycosis, [[Mucormycosis]]): FDA-approved in 3/15
    • May be used as an alternative to posaconazole (see Posaconazole, [[Posaconazole]])

Pharmacology

  • Triazole Anti-Fungal: formulated as a pro-drug (isavuconazonium sulfate)
    • Mechanism: inhibition of lanosterol 14 alpha-demethylase (enzyme which converts lanosterol to ergosterol by demethylation) -> disrupted fungal cell membrane structure
    • Mammalian cells are resistant to demethylation inhibition by azoles, therefore, this effect is specific to fungi

Metabolism

  • xxx

Administration

  • PO: xx
  • IV: xx

Dose Adjustment

  • Hepatic
  • Renal

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx

References

  • xxx